Last reviewed · How we verify

radiochemotherapy,combination Cetuximab-FOLFOX

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

radiochemotherapy,combination Cetuximab-FOLFOX is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development. Also known as: objective response rate,combination Cetuximab-FOLFOX.

At a glance

Generic nameradiochemotherapy,combination Cetuximab-FOLFOX
Also known asobjective response rate,combination Cetuximab-FOLFOX
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about radiochemotherapy,combination Cetuximab-FOLFOX

What is radiochemotherapy,combination Cetuximab-FOLFOX?

radiochemotherapy,combination Cetuximab-FOLFOX is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes radiochemotherapy,combination Cetuximab-FOLFOX?

radiochemotherapy,combination Cetuximab-FOLFOX is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is radiochemotherapy,combination Cetuximab-FOLFOX also known as anything else?

radiochemotherapy,combination Cetuximab-FOLFOX is also known as objective response rate,combination Cetuximab-FOLFOX.

What development phase is radiochemotherapy,combination Cetuximab-FOLFOX in?

radiochemotherapy,combination Cetuximab-FOLFOX is in Phase 2.

Related